• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Drug administration schedule"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-20 of 36

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study 

      Briassoulis, E. Ch; Pentheroudakis, George; Timotheadou, H.; Rammou, D.; Pavlidis, Nicholas; Fountzilas, George (2004)
      We developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine ...

    • Article  

      Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study 

      Kosmidis, Paraskevas A.; Samantas, E.; Fountzilas, George; Pavlidis, Nicholas; Apostolopoulou, F.; Skarlos, Dimosthenis V. (1994)
      The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally ...

    • Article  

      Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma 

      Tsavaris, N.; Mylonakis, N.; Karvounis, N.; Bacoyiannis, Charalambos; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Stamatelos, G.; Kosmidis, Paraskevas A. (1994)
      From June 1985 to March 1993, 20 consecutive patients with histologically proven malignant mesothelioma were treated with cisplatin 100 mg/m2 i.v. infusion on day 1 and vinblastine 6 mg/m2 i.v. on day 1 and 8. Treatment ...

    • Article  

      Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer 

      Samantas, E.; Skarlos, Dimosthenis V.; Pectasides, Dimitrios; Nikolaidis, Pavlos; Kalofonos, H. P.; Mylonakis, N.; Vardoulakis, Th; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Fountzilas, George (1999)
      Sixty patients with poor prognostic features, either with extensive disease (ED) or limited disease (LD) small cell lung cancer (SCLC), were treated on an out-patient basis with Carboplatin 80 mg/m2 weekly for 3 weeks and ...

    • Article  

      Docetaxel (Taxotere™), a novel taxoid, in the treatment of advanced colorectal carcinoma: An EORTC Early Clinical Trials Group Study 

      Sternberg, Cora N.; Huinink, W. W. Ten Bokkel; Smyth, J. F.; Bruntsch, V.; Dirix, L. Y.; Pavlidis, Nicholas; Franklin, H. R.; Wanders, S.; Bail, N. Le; Kaye, Stanley B. (1994)
      Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were ...

    • Article  

      Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study 

      Pentheroudakis, George; Briassoulis, E. Ch; Kalofonos, H. P.; Fountzilas, George; Economopoulos, T.; Samelis, G.; Koutras, A. K.; Karina, M.; Xiros, N.; Samantas, E.; Bamias, A. T.; Pavlidis, Nicholas (2008)
      Introduction. Taxane/platinum combinations exhibit synergistic cytotoxicity and activity against a broad range of solid tumours. We sought to optimise the regimen as a suitable outpatient palliative treatment for cancer ...

    • Article  

      Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes 

      Fountzilas, George; Nikolaides, C.; Aravantinos, Gerasimos; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Papakostas, P.; Stathopoulos, G. P.; Kontostolis, E.; Bafaloukos, Dimitrios; Pavlidis, Nicholas (1998)
      Forty-one patients with operable breast cancer and ≥ 10 positive axillary lymph nodes were treated with 6 cycles of dose-dense adjuvant chemotherapy consisting of epirubicin (100 mg/m2) every 2 weeks with G-CSF support. A ...

    • Article  

      Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial 

      Fountzilas, George; Dafni, U.; Papadimitriou, C.; Timotheadou, E.; Gogas, H.; Eleftheraki, A. G.; Xanthakis, I.; Christodoulou, C.; Koutras, A. K.; Papandreou, C. N.; Papakostas, P.; Miliaras, S.; Markopoulos, C.; Dimitrakakis, C.; Korantzopoulos, Panagiotis; Karanikiotis, C.; Bafaloukos, Dimitrios; Kosmidis, Paraskevas A.; Samantas, E.; Varthalitis, I.; Pavlidis, Nicholas; Pectasides, Dimitrios; Dimopoulos, M. A. (2014)
      Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...

    • Article  

      Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer 

      Razi, E. D.; Dimopoulos, M. A.; Bafaloukos, Dimitrios; Papadimitriou, C.; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Briassoulis, E. Ch; Samantas, E.; Keramopoulos, A.; Pavlidis, Nicholas; Kosmidis, Paraskevas A.; Fountzilas, George (2001)
      The purpose of this study was to evaluate the activity and toxicity profile of dose-dense sequential chemotherapy with epirubicin (EPI) and paclitaxel in advanced breast cancer (ABC). From January to September 1997, 41 ...

    • Article  

      Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the hellenic cooperative oncology group 

      Fountzilas, George; Papadimitriou, C.; Dafni, U.; Bafaloukos, Dimitrios; Skarlos, Dimosthenis V.; Moulopoulos, L. A.; Razi, E. D.; Kalofonos, H. P.; Aravantinos, Gerasimos; Briassoulis, E. Ch; Papakostas, P.; Abela, K.; Gogas, H.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)
      Purpose: To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC). Patients and Methods: From October 1997 until May 1999, ...

    • Article  

      Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer 

      Briassoulis, E. Ch; Pappas, P.; Puozzo, C.; Ch, F. Tolis; Fountzilas, George; Dafni, U.; Marselos, M.; Pavlidis, Nicholas (2009)
      Aim: To determine the safe dose range and pharmacokinetics of metronomic oral vinorelbine and obtain preliminary data on biomarkers and efficacy in patients with advanced cancer. Methods: Successive cohorts ofpatients ...

    • Article  

      Effect of intravenous nitroglycerin on lipid peroxidation after thrombolytic therapy for acute myocardial infarction 

      Ohlin, H.; Pavlidis, Nicholas; Ohlin, A. K. (1998)
      Free oxygen radicals are produced after coronary artery occlusion and reperfusion. Polyunsaturated fatty acids are oxidized by free radicals to lipid peroxides. Measurements of plasma malondialdehyde (MDA) formed by the ...

    • Article  

      Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study 

      Skarlos, Dimosthenis V.; Kalofonos, H. P.; Fountzilas, George; Dimopoulos, M. A.; Pavlidis, Nicholas; Razi, E. D.; Economopoulos, T.; Pectasides, Dimitrios; Gogas, H.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Klouvas, G. D.; Kyratzis, G.; Aravantinos, Gerasimos (2005)
      Background: A phase II study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in patients with platinum- and/or taxane-resistant/refractory ...

    • Article  

      High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study 

      Fountzilas, George; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Makrantonakis, P.; Tsavaris, N.; Kalogera-Fountzila, Anna; Giannakakis, T.; Beer, M.; Kosmidis, Paraskevas A. (1991)
      Fifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin. Even though the study was started with a dose schedule of 110 mg/m2 every 3 weeks, the average treatment interval was 26 days and the ...

    • Article  

      High‐dose epirubicin and r‐met‐hu G‐CSF (Filgrastim) in the treatment of patients with advanced breast cancer: A hellenic cooperative oncology group study 

      Fountzilas, George; Skarlos, Dimosthenis V.; Katsohis, C.; Pavlidis, Nicholas; Giannakakis, T.; Bafaloukos, Dimitrios; Fahantidis, E.; Klouvas, G. D.; Beer, M.; Kosmidis, Paraskevas A. (1995)
      The delivery of high‐dose epirubicin in patients with advanced breast cancer usually entails serious myelotoxicity and frequent treatment delays. Concurrent administration of G‐CSF probably allows the administration of ...

    • Article  

      Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in patients with advanced gastrointestinal carcinomas: A phase I dose-finding and pharmacokinetic study 

      Bamias, A. T.; Syrigos, K.; Fountzilas, George; Tzamakou, E.; Soulti, K.; Karavasilis, V.; Alamanos, Y. P.; Christodoulou, C.; Pavlidis, Nicholas (2004)
      5-Fluorouracil (5FU) and cisplatin are commonly used in the treatment of gastric cancer. Continuous 5FU appears to be more effective and less toxic than bolus administration, while increasing the dose intensity of cisplatin ...

    • Article  

      Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study 

      Briassoulis, E. Ch; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Xiros, N.; Aravantinos, Gerasimos; Samantas, E.; Kalofonos, H. P.; Makatsoris, T.; Mylonakis, N.; Papakostas, P.; Skarlos, Dimosthenis V.; Varthalitis, I.; Pavlidis, Nicholas (2008)
      Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with ...

    • Article  

      Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial 

      Kosmidis, Paraskevas A.; Mylonakis, N.; Skarlos, Dimosthenis V.; Samantas, E.; Dimopoulos, M. A.; Papadimitriou, C.; Kalofonos, H. P.; Pavlidis, Nicholas; Nikolaides, C.; Papaconstantinou, C.; Fountzilas, George (2000)
      Purpose: The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports of moderate toxicity, reasonable activity and easy outpatient administration. Purpose of our present ...

    • Article  

      Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study. 

      Kosmidis, Paraskevas A.; Mylonakis, N.; Fountzilas, George; Samantas, E.; Athanasiades, A.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (1997)
      A recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the ...

    • Article  

      Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group 

      Fountzilas, George; Stathopoulos, G. P.; Nikolaides, C.; Kalogera-Fountzila, Anna; Kalofonos, H. P.; Nikolaou, A.; Bacoyiannis, Charalambos; Samantas, E.; Papadimitriou, C.; Kosmidis, Paraskevas A.; Daniilidis, J.; Pavlidis, Nicholas (1999)
      Background: Paclitaxel as monotherapy or in combination with other drugs has demonstrated significant activity in patients with squamous cell carcinoma of the head and neck region (SCCHN). Preclinical studies have shown ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD